Does lamotrigine (Lamictal) interfere with folate conversion, and does synthetic folic acid, but not natural folate, reduce lamotrigine’s therapeutic effectiveness?

Lamotrigine's Interaction with Folate Metabolism

Yes, lamotrigine (Lamictal) does interfere with folate conversion by inhibiting dihydrofolate reductase, and synthetic folic acid—but not natural folate forms—appears to reduce lamotrigine's therapeutic effectiveness in bipolar depression. This interaction has significant clinical implications that warrant careful consideration when prescribing these agents together.

Lamotrigine's Effect on Folate Metabolism

Lamotrigine inhibits dihydrofolate reductase, the enzyme that catalyzes the reduction of dihydrofolate to tetrahydrofolate, which may interfere with nucleic acid and protein biosynthesis 1. This mechanism is well-established in the FDA drug labeling for Lamictal.

• Animal studies demonstrate that oral lamotrigine administration during organogenesis reduces fetal, placental, and maternal folate concentrations 1
• In male rats given repeated oral lamotrigine doses, reduced folate concentrations were partially restored when supplemented with folinic acid (not folic acid) 1
• This interference with folate metabolism is distinct from other anticonvulsants like methotrexate, which also inhibit dihydrofolate reductase, or sulphasalazine, which causes folate malabsorption 2

Folic Acid's Paradoxical Effect on Lamotrigine Efficacy

The most compelling evidence comes from the CEQUEL trial, which demonstrated that synthetic folic acid nullifies lamotrigine's antidepressant effect in bipolar depression 3. This is a critical finding that contradicts conventional wisdom about folate supplementation.

Key Findings from CEQUEL Trial:

• Lamotrigine alone improved depressive symptoms with a mean difference of -4.14 points on QIDS-SR16 compared to placebo (p=0.004) 3
• When combined with folic acid, lamotrigine showed no benefit: mean difference of only 0.12 points (p=0.931) 3
• There was a significant interaction effect (p=0.028), with folic acid reducing lamotrigine's effectiveness at 12 weeks 3
• This effect persisted at 52 weeks, with lamotrigine showing a mean difference of -2.69 points (p=0.017) 3

Mechanism of the Interaction:

This is NOT a pharmacokinetic interaction—lamotrigine serum levels were unaffected by folic acid supplementation 4. The mechanism appears to be pharmacodynamic:

• The negative impact of folic acid on lamotrigine response was limited to COMT Met carriers, suggesting a genetic modulation of the interaction 4
• MTHFR and FOLH1 polymorphisms had no effect on this interaction 4
• Biochemical measures of one-carbon metabolism did not correlate with clinical outcomes 4

Clinical Implications and Recommendations

For Patients on Lamotrigine:

Avoid routine synthetic folic acid supplementation in patients taking lamotrigine for mood disorders, unless there is a specific indication 3. The evidence suggests:

• Natural dietary folates (from leafy greens, pulses, eggs, nuts) do not appear to have the same negative interaction 5
• If folate supplementation is medically necessary (e.g., pregnancy planning), consider folinic acid (5-formyltetrahydrofolate) instead of synthetic folic acid, as animal data suggest this form may be better tolerated with lamotrigine 1
• The biologically active form 5-methyltetrahydrofolate (5-MTHF) may also be preferable, though this has not been specifically studied with lamotrigine 5

Special Considerations for Pregnancy:

This creates a clinical dilemma, as women of childbearing age on antiepileptic drugs require folate supplementation to prevent neural tube defects:

• Women planning pregnancy should receive 0.4 mg (400 mcg) daily of folic acid, or 4 mg daily if they have a prior history of neural tube defects 6, 7, 8
• For women on lamotrigine specifically, consider using folinic acid rather than folic acid, based on the animal data showing partial restoration of folate status 1
• One study showed that supplemental folinic acid ameliorated lamotrigine-induced fetal malformations in mice and restored folate status 9
• High-dose folic acid (5 mg/day or more) usage during pregnancy has increased significantly over time (43.9% to 81%) in epilepsy registries 10

Monitoring and Alternative Approaches:

• Patients on lamotrigine should have folate status monitored through serum/plasma folate or RBC folate levels 5
• Consider dietary optimization with folate-rich foods (200-300g of pulses or 400g of leafy green vegetables cover daily requirements) 5
• Food folates have lower bioavailability than synthetic folic acid (1 mg food folate = 0.6 mg folic acid from fortified food) but may not interfere with lamotrigine efficacy 5

Common Pitfalls to Avoid:

• Do not assume all folate forms are equivalent—the CEQUEL trial specifically showed synthetic folic acid interferes with lamotrigine, but natural folates and folinic acid may behave differently 3, 4
• Do not discontinue necessary folate supplementation in pregnancy—instead, consider switching to folinic acid or 5-MTHF 9
• Do not ignore this interaction in clinical practice—only 37% of women on antiepileptic drugs take folic acid, suggesting widespread under-recognition of supplementation needs 11